Scarica l'app Stockscreener
35.53
5.34%
1.80
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$33.73
Aprire:
$33.89
Volume 24 ore:
21.01M
Relative Volume:
1.95
Capitalizzazione di mercato:
$13.67B
Reddito:
$5.06B
Utile/perdita netta:
$-2.22B
Rapporto P/E:
-6.1048
EPS:
-5.82
Flusso di cassa netto:
$-3.96B
1 W Prestazione:
+7.70%
1M Prestazione:
-1.00%
6M Prestazione:
-59.00%
1 anno Prestazione:
-59.44%
Intervallo 1D:
$33.18
$35.97
Intervallo di 1 settimana:
$32.04
$36.98
Portata 52W:
$29.25
$170.47
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Confronta MRNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
35.53 | 13.67B | 5.06B | -2.22B | -3.96B | -5.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
CIBC Asset Management Inc Lowers Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna Stock: The Future Unveiled! Innovative Tech to Drive Explosive Growth! - Reporteros del Sur -
Market plunges after new Coronavirus reported in Wuhan but Pfizer and Moderna stock soars - Daily Mail
Why Moderna Inc. (MRNA) Surged On Friday? - Insider Monkey
Moderna (NASDAQ:MRNA) Trading 8.8% HigherWhat's Next? - MarketBeat
Moderna and Other Vaccine Stocks Climb After Coronavirus News From China - MSN
Chinese researchers find bat virus enters human cells via same pathway as COVID -February 21, 2025 at 05:56 pm EST - Marketscreener.com
Moderna and Other Vaccine Stocks Climb Amid Concerns About Coronavirus Study in China - Yahoo Finance
Moderna Sees Unusually High Options Volume (NASDAQ:MRNA) - MarketBeat
Moderna (NASDAQ:MRNA) Trading Up 8.8%Time to Buy? - MarketBeat
Moderna (NASDAQ:MRNA) Trading Down 7.9% Following Analyst Downgrade - MarketBeat
Moderna, Novavax rise as new bat coronavirus identified in China - MSN
Moderna stock rises amid new virus concerns By Investing.com - Investing.com Australia
Analyst calls of the week: Rivian, Block, Moderna, Bumble... - Proactive Investors USA
Moderna, Inc. SEC 10-K Report - TradingView
Rx Rundown: Moderna, Sanofi, GSK and more - MM+M Online
Meitav Investment House Ltd. Sells 184,043 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Should You Buy, Hold or Sell Moderna Stock Post Q4 Earnings Release? - MSN
Moderna, Inc. to Host Earnings Call - ACCESS Newswire
MRNA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Moderna, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Baillie Gifford & Co. Lowers Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Levi & Korsinsky Notifies Moderna, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineMRNA - ACCESS Newswire
Moderna (NASDAQ:MRNA) Price Target Lowered to $78.00 at UBS Group - MarketBeat
Moderna stock plunges nearly 17% after company lowers 2025 sales forecast by $1 billion - MSN
Will Moderna Stock Drop to $25? 1 Wall Street Analyst Thinks So. - Nasdaq
Moderna (MRNA) Expected to Announce Earnings on Thursday - MarketBeat
Intrinsic Value Partners LLC Lowers Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna's (MRNA) "Sector Perform" Rating Reiterated at Royal Bank of Canada - MarketBeat
Wall Street Thinks This Beaten-Down Growth Stock Can Soar 85% in 2025. Should You Buy It Now? - MSN
EMA Urged Pfizer And Moderna To Boost Production Volume Of COVID Vax - BW Healthcare World
UBS Adjusts Moderna Price Target to $78 From $96, Maintains Buy Rating -February 19, 2025 at 10:21 am EST - Marketscreener.com
Why Moderna (MRNA) Went Up on Tuesday? - Yahoo Finance
Moderna: A Generational Opportunity for Investors in 2025 - MarketBeat
Flagship Pioneering Appoints Paul Owen as CEO-Partner and CEO of YourBio Health - Quantisnow
Moderna (NASDAQ:MRNA) Stock Rating Lowered by Barclays - MarketBeat
Moderna price target lowered to $78 from $96 at UBS - TipRanks
Trump’s Hammer Hits FDA, Moderna Falls Further and Patent Cliffs Loom - BioSpace
Barclays Downgrades Moderna (WBAG:MRNA) - Nasdaq
Rep. Julie Johnson Sells Moderna, Inc. (NASDAQ:MRNA) Shares - MarketBeat
Louisiana State Employees Retirement System Sells 30,100 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Q4 2024 Earnings Call Transcript - MSN
Barclays Downgrades Moderna (MRNA) - MSN
Barclays Downgrades Moderna (BIT:1MRNA) - Nasdaq
Moderna Downgraded by Barclays as Policy Risks and Weak Revenue Weigh on Outlook - GuruFocus.com
Why Moderna (MRNA) Stock Is Up Today By Stock Story - Investing.com Canada
Moderna's Stock Increases by 11.8% Despite Market ChallengesNews and Statistics - IndexBox, Inc.
MRNA: Moderna Stock Rises on Financial Results Despite Downgrade - GuruFocus.com
Moderna rises 8% even as Barclays downgrades - Seeking Alpha
Moderna shares move higher as investors look beyond Q4 losses - Proactive Investors UK
Why Moderna (MRNA) Stock Is Up Today - Financial Content
Analyst Confident In Moderna's Cancer Vaccine But Highlights Other Challenges - Benzinga
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):